Cargando…
Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hyp...
Autores principales: | Melnick, Stephen, Rajagopalan, Priya, Lynn, Theresa, Donato, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197014/ https://www.ncbi.nlm.nih.gov/pubmed/30357044 http://dx.doi.org/10.1080/20009666.2018.1527667 |
Ejemplares similares
-
Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
por: Varshney, Navya, et al.
Publicado: (2021) -
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020) -
Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020) -
Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020) -
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)